Regulation of caspase 9 RNA splicing in NSCLC cancer
Regulation of caspase 9 RNA splicing in NSCLC cancer
批准号:
8305473
负责人:
CHARLES E. CHALFANT
金额:
$31.02万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-07-21 至 2015-04-30
关键词:
AccountingAffinityAlternative SplicingAnchorage-Independent GrowthApoptoticApplications GrantsBindingBiologicalCancer ModelCaspaseCatalytic DomainCause of DeathCessation of lifeClinicClinical PathologyCytochromesDataDeveloped CountriesDevelopmentDiseaseDistalEffectivenessElementsEnhancersEpidermal Growth Factor ReceptorEpithelial CellsErlotinibExclusionExonsGenerationsGoalsHeterogeneous-Nuclear Ribonucleoprotein LHeterogeneous-Nuclear Ribonucleoprotein UHumanLaboratoriesLiteratureMaintenanceMalignant NeoplasmsMalignant neoplasm of lungMediator of activation proteinMutationNon-Small-Cell Lung CarcinomaOncogenicPI3K/AKTPathway interactionsPatientsPhenotypePhosphorylationPhysiologicalProto-Oncogene Proteins c-aktRNARNA SplicingRadiationRegulationReportingRepressionResistanceRoleSignal PathwaySignal TransductionTranscriptUnited StatesUnresectableWomananti-cancer therapeuticcancer cellcaspase-9cell transformationchemotherapeutic agentchemotherapyclinically relevantcombatin vivomRNA Precursormennovel therapeuticsoutcome forecastpalliativepreclinical studytumortumorigenic
中文摘要
描述(由申请人提供):今天,肺癌是工业化国家男性和女性死亡的主要原因,估计占美国所有癌症死亡人数的28%。非小细胞肺癌(NSCLC)占肺癌的大多数,预后较差,中位生存期不到12个月。大多数患者患有不可切除的疾病,目前的治疗选择化疗和放疗充其量是姑息治疗。因此,需要新的策略来治疗非小细胞肺癌,以影响这种疾病。在这项研究中,我们将重点放在非小细胞肺癌模型上,以研究调节非小细胞肺癌细胞/肿瘤化疗敏感性、产生和维持的远端信号机制。具体而言,该资助申请侧重于调节hnRNP - L功能和caspase - 9选择性剪接的细胞信号通路。caspase 9的表达是通过包含或排除四个外显子盒(外显子3,4,5和6)的选择性剪接来调节的。将该外显子盒包含在成熟转录本中产生促凋亡caspase 9 (caspase 9a),而将其排除则产生抗凋亡caspase 9b。我们实验室的研究表明,非小细胞肺癌肿瘤存在caspase 9/caspase 9b比例失调,类似于抗凋亡/化疗耐药表型。我们实验室的后续研究表明,caspase 9的选择性剪接在非小细胞肺癌细胞的锚定独立生长(AIG)、非转化人支气管上皮细胞中EGFR突变诱导的AIG以及厄洛替尼敏感性中具有重要功能。从机制上讲,我们的实验室在外显子3中发现了一个外显子剪接沉默子(C9/E3-ESS),它调节caspase 9前mrna的外显子3,4,5和6盒的包含。hnRNP L被证明与该RNA顺式元件结合,并抑制外显子盒的包含。重要的是,hnRNP L在ser52上的磷酸化(仅在转化细胞中观察到)是抑制外显子3,4,5,6盒所必需的。最后,通过caspase 9的选择性剪接,hnRNP L的ser52磷酸化被证明是NSCLC细胞致瘤能力的必要介质。这些关键机制是转化细胞所特有的,可翻译为70%的非小细胞肺癌,并且在致癌途径的极端远端。因此,这些远端机制是开发新的抗癌疗法的合理和高度期望的目标。本研究的总体目标是确定调节外显子3定义的机制和细胞信号通路,从而确定caspase 9的选择性剪接。此外,我们正在提出临床前研究,以确定这些机制以及caspase 9b的特异性靶向是否为治疗非小细胞肺癌的有效靶点,并提高目前临床使用的化疗药物的有效性。
英文摘要
DESCRIPTION (provided by applicant): Today, lung cancer is the leading cause of death in both men and women in industrialized countries, accounting for an estimated 28% of all cancer deaths in the United States. Non-small cell lung cancers (NSCLC) represent the majority of lung cancers and carry a poor prognosis with a median survival of less than 12 months. Most patients present with unresectable disease and current treatment options of chemotherapy and radiation are palliative at best. Therefore, new strategies are needed in the treatment of NSCLC in order to impact this disease. In this study, we are focusing on NSCLC models for examining distal signaling mechanisms that modulate the chemotherapy sensitivity, generation, and maintenance of NSCLC cells/tumors. Specifically, the grant application focuses on the cell signaling pathways regulating both hnRNP L function and the alternative splicing of caspase 9. The expression of caspase 9 is regulated by alternative splicing via the inclusion or exclusion of a four exon cassette (exons 3, 4, 5, and 6). Inclusion of this exon cassette into the mature transcript produces the pro-apoptotic caspase 9 (caspase 9a) while the exclusion produces the anti-apoptotic caspase 9b. Studies from our laboratory have demonstrated that NSCLC tumors present with a dysregulated ratio of caspase 9/caspase 9b analogous to an anti-apoptotic/chemotherapy resistance phenotype. Subsequent studies by our laboratory demonstrated that the alternative splicing of caspase 9 had important functions in anchorage-independent growth (AIG) in NSCLC cells, AIG induced by EGFR mutation in non-transformed human bronchial epithelial cells, and erlotinib sensitivity. Mechanistically, our laboratory identified an exonic splicing silencer (C9/E3-ESS) in exon 3 that regulates the inclusion of the exon 3, 4, 5, and 6 cassette of caspase 9 pre-mRNA. hnRNP L was shown to associate with this RNA cis-element, and repress the inclusion of the exon cassette. Importantly, phosphorylation of hnRNP L on ser52 (observed only in transformed cells) was required for repression of the exon 3,4,5,6 cassette. Lastly, ser52 phosphorylation of hnRNP L was shown as a required mediator of the tumorigenic capacity of NSCLC cells via the alternative splicing of caspase 9. These key mechanisms are specific to transformed cells, translatable to >70% of NSCLCs, and at an extreme distal point in oncogenic pathways. Therefore, these distal mechanisms are plausible and highly desired targets for the development of new anti-cancer therapeutics. The overall goal of this study is to determine the mechanisms and cell signaling pathways regulating the definition of exon 3, and thus the alternative splicing of caspase 9. Furthermore, we are proposing pre-clinical studies to determine whether these mechanisms as well as specific targeting of caspase 9b are effective targets for treating NSCLC as well as enhancing the effectiveness of current chemotherapeutic agents used in the clinic.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
iPLA2beta-mediated alternative splicing and beta-cell death in type 1 diabetes
-
批准号:10594556
-
项目类别:
-
资助金额:$47.13万
-
财政年份:2021
-
负责人:CHARLES E. CHALFANT
-
依托单位:
The role and mechanistic regulation of cPLA2alpha in eicosanoid biosynthesis and wound healing
-
批准号:10644976
-
项目类别:
-
资助金额:$45.72万
-
财政年份:2021
-
负责人:CHARLES E. CHALFANT
-
依托单位:
The role and mechanistic regulation of cPLA2alpha in eicosanoid biosynthesis and wound healing
-
批准号:10614111
-
项目类别:
-
资助金额:$22.28万
-
财政年份:2021
-
负责人:CHARLES E. CHALFANT
-
依托单位:
The role and mechanistic regulation of cPLA2alpha in eicosanoid biosynthesis and wound healing
-
批准号:10318663
-
项目类别:
-
资助金额:$46.36万
-
财政年份:2021
-
负责人:CHARLES E. CHALFANT
-
依托单位:
The role and mechanistic regulation of cPLA2alpha in eicosanoid biosynthesis and wound healing
-
批准号:10156764
-
项目类别:
-
资助金额:$25.74万
-
财政年份:2021
-
负责人:CHARLES E. CHALFANT
-
依托单位:
iPLA2beta-mediated alternative splicing and beta-cell death in type 1 diabetes
-
批准号:10554009
-
项目类别:
-
资助金额:$54.28万
-
财政年份:2021
-
负责人:CHARLES E. CHALFANT
-
依托单位:
The role of ceramide kinase in mitophagy
-
批准号:10645030
-
项目类别:
-
资助金额:$35.33万
-
财政年份:2020
-
负责人:CHARLES E. CHALFANT
-
依托单位:
The role of ceramide kinase in mitophagy
-
批准号:10265578
-
项目类别:
-
资助金额:$6.03万
-
财政年份:2020
-
负责人:CHARLES E. CHALFANT
-
依托单位:
The role of ceramide kinase in mitophagy
-
批准号:10413213
-
项目类别:
-
资助金额:$36.14万
-
财政年份:2020
-
负责人:CHARLES E. CHALFANT
-
依托单位:
The role of ceramide kinase in mitophagy
-
批准号:10593576
-
项目类别:
-
资助金额:$21.58万
-
财政年份:2020
-
负责人:CHARLES E. CHALFANT
-
依托单位:
BLRD Research Career Scientist Award Application
-
批准号:9763685
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:CHARLES E. CHALFANT
-
依托单位:
BLRD Research Career Scientist Award Application
-
批准号:10614329
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:CHARLES E. CHALFANT
-
依托单位:
BLRD Research Career Scientist Award Application
-
批准号:10618274
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:CHARLES E. CHALFANT
-
依托单位:
BLRD Research Career Scientist Award Application
-
批准号:10454227
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:CHARLES E. CHALFANT
-
依托单位:
BLRD Research Career Scientist Award Application
-
批准号:9911978
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:CHARLES E. CHALFANT
-
依托单位:
BLRD Research Career Scientist Award Application
-
批准号:10265424
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:CHARLES E. CHALFANT
-
依托单位:
The roles of ceramide and its derivatives in A. phagocytophilum pathogenesis
-
批准号:9925725
-
项目类别:
-
资助金额:$56.8万
-
财政年份:2018
-
负责人:CHARLES E. CHALFANT
-
依托单位:
The roles of ceramide and its derivatives in A. phagocytophilum pathogenesis
-
批准号:10736608
-
项目类别:
-
资助金额:$74.27万
-
财政年份:2018
-
负责人:CHARLES E. CHALFANT
-
依托单位:
The roles of ceramide and its derivatives in A. phagocytophilum pathogenesis
-
批准号:10197752
-
项目类别:
-
资助金额:$56.8万
-
财政年份:2018
-
负责人:CHARLES E. CHALFANT
-
依托单位:
The roles of ceramide and its derivatives in A. phagocytophilum pathogenesis
-
批准号:10402829
-
项目类别:
-
资助金额:$56.8万
-
财政年份:2018
-
负责人:CHARLES E. CHALFANT
-
依托单位:
海外基金